Brighton Jones LLC Has $1.31 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Brighton Jones LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 245.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,018 shares of the medical equipment provider’s stock after acquiring an additional 12,091 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $1,311,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC increased its holdings in Boston Scientific by 87.7% in the second quarter. Intech Investment Management LLC now owns 77,862 shares of the medical equipment provider’s stock worth $5,996,000 after purchasing an additional 36,370 shares in the last quarter. Mark Sheptoff Financial Planning LLC boosted its position in shares of Boston Scientific by 892.5% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 526 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 473 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Boston Scientific by 16.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 144,824 shares of the medical equipment provider’s stock valued at $11,134,000 after buying an additional 20,142 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in Boston Scientific by 23.5% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 32,146 shares of the medical equipment provider’s stock worth $2,476,000 after purchasing an additional 6,120 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV boosted its position in Boston Scientific by 1.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 58,969 shares of the medical equipment provider’s stock worth $4,548,000 after purchasing an additional 888 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 20,949 shares of company stock valued at $1,627,877 over the last ninety days. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. BTIG Research boosted their target price on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Citigroup upped their target price on Boston Scientific from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Raymond James upped their price objective on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Truist Financial upped their price objective on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Finally, Morgan Stanley increased their target price on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.38.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $83.92 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The business’s 50 day moving average price is $78.72 and its 200-day moving average price is $74.63. The firm has a market capitalization of $123.12 billion, a PE ratio of 70.52, a P/E/G ratio of 2.75 and a beta of 0.79. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $84.89.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. As a group, equities research analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.